Scarica l'app Stockscreener
59.54
6.16%
-3.91
Dopo l'orario di chiusura:
59.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$63.45
Aprire:
$62.82
Volume 24 ore:
2.89M
Relative Volume:
1.42
Capitalizzazione di mercato:
$9.32B
Reddito:
$1.22B
Utile/perdita netta:
$77.95M
Rapporto P/E:
121.71
EPS:
0.4892
Flusso di cassa netto:
$224.06M
1 W Prestazione:
-9.60%
1M Prestazione:
-10.55%
6M Prestazione:
+12.70%
1 anno Prestazione:
-11.71%
Intervallo 1D:
$58.04
$63.45
Intervallo di 1 settimana:
$58.04
$67.60
Portata 52W:
$46.01
$72.16
Bio Techne Corp Stock (TECH) Company Profile
Nome
Bio Techne Corp
Settore
Industria
Telefono
612-379-8854
Indirizzo
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
59.54 | 9.93B | 1.22B | 77.95M | 224.06M | 0.4892 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-07-22 | Ripresa | Stephens | Overweight |
| 2025-07-09 | Iniziato | TD Cowen | Buy |
| 2025-05-30 | Iniziato | Wells Fargo | Overweight |
| 2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Iniziato | Evercore ISI | Outperform |
| 2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-08 | Iniziato | Scotiabank | Sector Outperform |
| 2024-02-02 | Downgrade | Stifel | Buy → Hold |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-08-28 | Iniziato | William Blair | Outperform |
| 2023-01-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Aggiornamento | Stifel | Hold → Buy |
| 2021-01-25 | Reiterato | The Benchmark Company | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-07-15 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Downgrade | Stifel | Buy → Hold |
| 2020-05-14 | Iniziato | The Benchmark Company | Buy |
| 2020-01-08 | Ripresa | Stephens | Overweight |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-02 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-14 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-10-17 | Iniziato | Goldman | Neutral |
| 2018-06-15 | Iniziato | Argus | Buy |
| 2017-07-13 | Iniziato | Wells Fargo | Market Perform |
| 2017-02-09 | Iniziato | Citigroup | Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Buy |
| 2016-11-10 | Ripresa | Leerink Partners | Outperform |
| 2015-01-21 | Reiterato | Robert W. Baird | Outperform |
| 2013-09-20 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
Mostra tutto
Bio Techne Corp Borsa (TECH) Ultime notizie
(TECH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call - Finviz
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings - Yahoo Finance
What Are Wall Street Analysts' Target Price for Bio-Techne Stock? - inkl
Bio-Techne Announces Changes to its Leadership Team - Investing News Network
Ex-Dividend Reminder: Bio-Techne, 3M and Eli Lilly - Nasdaq
Madison Asset Management LLC Acquires Shares of 744,651 Bio-Techne Corp $TECH - MarketBeat
Bio-Techne (NASDAQ:TECH) Stock Rating Upgraded by Zacks Research - MarketBeat
Bio-Techne Corp (NASDAQ:TECH) Passes Key Quality Investing Screen - ChartMill
Baader Bank Aktiengesellschaft Buys 38,082 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne: How Spatial Biology Innovation Is Powering a Strategic Comeback! - Smartkarma
Azzad Asset Management Inc. ADV Has $774,000 Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
How Flat Sales, Higher EPS, and New Organoid Tools At Bio-Techne (TECH) Have Changed Its Investment Story - Yahoo Finance
Bio-Techne stock price target raised to $65 from $60 at Stifel By Investing.com - Investing.com Nigeria
New York State Common Retirement Fund Sells 465,634 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne stock price target raised to $65 from $60 at Stifel - Investing.com UK
Wells Fargo & Company Issues Positive Forecast for Bio-Techne (NASDAQ:TECH) Stock Price - MarketBeat
TECH Stock Update: Wells Fargo Raises Price Target for Bio-Techne | TECH Stock News - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Cor - GuruFocus
Bio-Techne (TECH) Sees Target Price Raised by Stifel | TECH Stoc - GuruFocus
UBS Maintains Buy Rating on Bio-Techne (TECH) with Raised Price Target | TECH Stock News - GuruFocus
Citigroup Raises Price Target for Bio-Techne (TECH) to $80.00 | - GuruFocus
7 Analysts Assess Bio-Techne: What You Need To Know - Benzinga
Assessing Bio-Techne (TECH) Valuation After Earnings Beat And New Research Product Launches - simplywall.st
Tech Stock Update: Evercore ISI Group Raises Price Target for TE - GuruFocus
TD Cowen Maintains Buy Rating on Bio-Techne (TECH) and Raises Pr - GuruFocus
Leerink Partners Adjusts Price Target on Bio-Techne to $80 From $75, Maintains Outperform Rating - marketscreener.com
Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript - Insider Monkey
Techne Corp. (TECH) Q2 Earnings Report: Results Top Analyst ForecastsNews and Statistics - IndexBox
TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets - Finviz
Trading Recap: Is Bio Techne Corporation showing insider buying2025 Analyst Calls & Advanced Technical Signal Analysis - baoquankhu1.vn
Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales - The Globe and Mail
Bio-Techne Corp Plans Quarterly Dividend of $0.08 (NASDAQ:TECH) - MarketBeat
Bio-Techne Releases Second Quarter Fiscal 2026 Results - Investing News Network
Bio-Techne Corp (TECH) Q2 2026 Earnings Call Highlights: Strateg - GuruFocus
Bio-Techne (NASDAQ:TECH) Shares Up 7% on Strong Earnings - MarketBeat
Earnings call transcript: Bio-Techne beats Q2 2026 EPS and revenue forecasts - Investing.com Nigeria
Biotech firm Bio-Techne beats quarterly estimates on strength in key unit - marketscreener.com
Bio-Techne (TECH) Q2 2026 Earnings Call Transcript - The Globe and Mail
Bio-Techne Q2 2026 Earnings Call Transcript - MarketBeat
Bio-Techne (NASDAQ:TECH) Announces Quarterly Earnings Results - MarketBeat
Bio-techne announces $0.08 quarterly dividend payment By Investing.com - Investing.com South Africa
TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up - Yahoo Finance
Bio-Techne Corp announces dividend of $0.08 per share for Q4 2025 - marketscreener.com
Bio-Techne Fiscal Q2 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Bio-Techne (TECH) Surpasses Q2 Revenue Expectations - GuruFocus
Insights into Bio-Techne Q2 Earnings - Benzinga
Bio-Techne Corp (NASDAQ:TECH) Reports Q2 Earnings Beat, Meets Revenue Forecasts - ChartMill
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026 - marketscreener.com
Bio-Techne Earnings Review: Q2 Summary - Benzinga
Earnings Breakdown: Bio-Techne Q2 - Benzinga
Bio Techne Corp Azioni (TECH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bio Techne Corp Azioni (TECH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McManus Matthew | President - Diag & Spatial Bio |
Feb 01 '26 |
Option Exercise |
0.00 |
4,621 |
0 |
9,356 |
| Hippel James | CFO |
Nov 03 '25 |
Option Exercise |
0.00 |
24,704 |
0 |
154,587 |
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Nov 03 '25 |
Option Exercise |
0.00 |
9,911 |
0 |
25,023 |
| Nusse Roeland | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,599 |
| Nusse Roeland | Director |
Aug 25 '25 |
Sale |
56.36 |
17,040 |
960,388 |
44,559 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,903 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Sale |
56.21 |
17,040 |
957,818 |
44,863 |
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):